A
Ayr Wellness Inc
CNSX:AYR.A
Ayr Wellness Inc
CNSX:AYR.A
Price:
0.155
CAD
Market Closed
Market Cap:
CA$18.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
A
|
Ayr Wellness Inc
CNSX:AYR.A
|
US |
|
RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret AS
IST:RTALB.E
|
TR |
|
Ihlas Ev Aletleri Imalat Sanayi ve Ticaret AS
IST:IHEVA.E
|
TR |
|
I-nexus Global PLC
LSE:INX
|
UK |
|
Ping An Insurance Group Co of China Ltd
SSE:601318
|
CN |
|
H
|
Haily Group Bhd
KLSE:HAILY
|
MY |
|
P
|
PetroVietnam Power Nhon Trach 2 JSC
VN:NT2
|
VN |
|
Fenix Resources Ltd
ASX:FEX
|
AU |
|
Middlesex Water Co
NASDAQ:MSEX
|
US |
|
Jay Shree Tea and Industries Ltd
NSE:JAYSREETEA
|
IN |
|
EFG International AG
SIX:EFGN
|
CH |
|
H
|
Huabao International Holdings Ltd
HKEX:336
|
HK |
|
A
|
Aspo Plc
XBER:ZYD
|
FI |
|
Kerry Logistics Network Ltd
HKEX:636
|
HK |
|
A
|
Al-Salam Real Estate Investment Trust
KLSE:ALSREIT
|
MY |
|
E
|
Echo Investment SA
WSE:ECH
|
PL |
|
Asia Allied Infrastructure Holdings Ltd
HKEX:711
|
HK |
|
Risecomm Group Holdings Ltd
HKEX:1679
|
CN |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of AYR.A.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
AYR.A
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
AYR.A Competitors Multiples
Ayr Wellness Inc Competitors
Ayr Wellness Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
A
|
Ayr Wellness Inc
CNSX:AYR.A
|
18.1m CAD | 0 | -0 | 4.7 | -2.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
